Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension - A report of the Japanese losartan therapy intended for the global renal protection in hypertensive patients (JLIGHT) study

Hypertension Research

Volumn 27, Issue 1, 2004, Pages 21-30

  Iino, Yasuhiko ^a   Hayashi, Matsuhiko ^b   Kawamura, Tetsuya ^c   Shiigai, Tatsuo ^d   Tomino, Yasuhiko ^e   Yamada, Kenichi ^f   Kitajima, Takeyuki ^c   Ideura, Terukuni ^g   Koyama, Akio ^h   Sugisaki, Tetsuzo ⁱ   Suzuki, Hiromichi ^j   Umemura, Satoshi ^k   Kawaguchi, Yoshindo ^k   Uchida, Shunya ^k   Kuwahara, Michio ^k   Yamazaki, Tsutomu ^k   Konta, T ^k   Takasaki, S ^k   Matsunaga, T ^k   Ishimitsu, T ^k   Matsuda, H ^k   Komatsumoto, S ^k   Utsugi, T ^k   Tomono, S ^k   Nagase, S ^k   Yamagata, K ^k   Hirayama, K ^k   Mase, K ^k   Aoyagi, K ^k   Kobayashi, M ^k   Nakamura, H ^k   Kikuchi, H ^k   Maeda, Y ^k   Okado, T ^k   Nakamoto, H ^k   Sugawara, S ^k   Handa, Y ^k   Iwahashi, C ^k   Kashiwagi, T ^k   Matsunobu, S ^k   Hosoya, T ^k   Tokudome, G ^k   Utsunomiya, Y ^k   Yamamoto, H ^k   Okonogi, H ^k   Shigematsu, T ^k   Miyazaki, Y ^k   Funabiki, K ^k   Horikoshi, S ^k   Fukui, M ^k   Ohmuro, H ^k   Tashiro, K ^k   Saruta, T ^k   Hayashi, K ^k   Nakao, T ^k   Okada, T ^k   Ohi, H ^k   Fujita, T ^k   Nakabayashi, K ^k   Ishizuka, S ^k   Hasegawa, A ^k   Mizuiri, S ^k   Sakai, K ^k   Suzuki, T ^k   Ibuki, C ^k   Yamanaka, H ^k   Tadera, T ^k   Nagasawa, K ^k   Yoshimura, A ^k   Kinugasa, E ^k   Morita, H ^k   Uda, S ^k   Hara, S ^k   Ubara, Y ^k   Katori, H ^k   Takemoto, F ^k   Tagami, T ^k   Yokota, M ^k   Yamada, A ^k   Matsushita, Y ^k   Sugimoto, T ^k   Tagawa, H ^k   Komatsu, Y ^k   Ohiwa, T ^k   Futatsuyama, M ^k   Kitazawa, K ^k   Shibata, T ^k   Honda, K ^k   Endo, M ^k   Ando, A ^k   Ikeda, K ^k   Yasuda, M ^k   Ito, T ^k   Takahashi, T ^k   Hori, Y ^k   Fukagawa, M ^k   Oose, T ^k   Shinoda, T ^k   Yoshimoto, H ^k   more..

^a NIPPON MEDICAL SCHOOL   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF TSUKUBA   (Japan)

^e JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f SAKURA NATIONAL HOSPITAL   (Japan)

^g SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^h UNIVERSITY OF TSUKUBA   (Japan)

ⁱ SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j SAITAMA MEDICAL UNIVERSITY   (Japan)

^k NONE

more..

Author keywords

Angiotensin; Hypertension; Losartan; Proteinuria; Renoprotection

Indexed keywords

ALANINE AMINOTRANSFERASE; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ASPARTATE AMINOTRANSFERASE; CALCIUM CHANNEL BLOCKING AGENT; GAMMA GLUTAMYLTRANSFERASE; LOSARTAN; POTASSIUM; URIC ACID;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CHRONIC GLOMERULONEPHRITIS; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; FEMALE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERURICEMIA; JAPAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; TRANSIENT ISCHEMIC ATTACK; URINARY EXCRETION;

AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; FEMALE; HUMANS; HYPERTENSION, RENAL; JAPAN; KIDNEY FAILURE, CHRONIC; LOSARTAN; MALE; MIDDLE AGED; PROTEINURIA; TREATMENT OUTCOME;

EID: 10744221480     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.27.21     Document Type: Article

References (27)

1. Burnier M, Brunner HR: Comparative antihypertensive effects of angiotensin II receptor antagonists. J Am Soc Nephrol 1999; 10: S278-S282.
2. Aros C, Remuzzi G: The rennin-angiotensin system in progression, remission and regression of chronic nephropathies. J Hypertens 2002; 20 (Suppl 3): S45-S53.
3. Jafar TH, Schmid CH, Landa L, et al: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. Ann Intern Med 2001; 135: 73-87.
4. Remuzzi G, Bertani T: Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 1990; 38: 384-394.
5. Powrie JK, Thomas S: Microalbuminuria: should lowering albumin excretion be a therapeutic goal? Int J Clin Pract 1999; 53: 492-493.
6. Fassbinder W, Quarder O, Waltz A: Treatment with carvedilol is associated with a significant reduction in microalbuminuria: a multicentre randomized study. Int J Clin Pract 1999; 53: 519-522.
7. de Boer E, Navis G, Wapstra F-H, de Jong PE, de Zeeuw D: Effect of proteinuria reduction on prevention of focal glomerulosclerosis by angiotensin-converting enzyme inhibition is modifiable. Kidney Int 1999; 56(Suppl 71): S42-S46.
8. Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
9. Iino Y, Hayashi M, Kawamura T, et al: Interim evidence on the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT STUDY). Clin Exp Nephrol 2003; 7: 221-230.
10. Proceedings of International Conference on Harmonization. Statistical Principles for Clinical Trials. February 5, 1998.
11. Maroni BJ, Steinman TI, Mitch WE: A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int 1985; 27: 58-65.
12. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997: 157: 2413-2446.
13. Chobanian AV, Bakris GL, Black HR, et al: The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003; 289: 2560-2572.
14. Tojo A, Onozato ML, Kurihara H, Sakai T, Goto A, Fujita T: Angiotensin II blockade restores albumin reabsorption in the proximal tubules of diabetic rats. Hypertens Res 2003; 26: 413-419.
15. Parving H-H, Lehnert H, Bröchner-Mortensen J, et al: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
16. Maruyama S, Hirano T, Sakaue T, Okada K, Ikejiri R, Adachi M: Low-dose candesartan cilexecil prevents early kidney damage in type 2 diabetic patients with mildly elevated blood pressure. Hypertens Res 2003; 26: 453-458.
17. Kuriyama S, Tomonari H, Tokudome G, et al: Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy. Hypertens Res 2002; 25: 849-855.
18. Nakao N, Yoshimura A, Morita H, Takeda M, Kayano T, Ideura T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 2003; 361: 117-124.
19. Weir MR, Dzau VJ: The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens 1999; 12: 205S-213S.
20. Nishimura H, Ichikawa I: What have we learned from gene targeting studies for the renin angiotensin system of the kidney? Intern Med 1999; 38: 315-323.
21. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-720.
22. Agodoa LY, Appel L, Bakris GL, et al: Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephroscrerosis: a randomized control trial. JAMA 2001; 285: 2719-2728.
23. Baba S, The J-MIND Study Group: Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract 2002; 54: 191-201.
24. Kumagai H, Hayashi K, Kumamaru H, Saruta T: Amlodipine is comparable to angiotensin-converting enzyme inhibitor for long-term renoprotection in hypertensive patients with renal dysfunction: a one-year, prospective, randomized study. Am J Hypertens 2000; 13: 980-985.
25. Jafar TH, Stark PC, Schmid CH, et al: Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001; 60: 1131-1140.
26. Mezzano SA, Ruiz-Ortega M, Egido J: Angiotensin II and renal fibrosis. Hypertension 2001; 38: 635-638.
27. Andersen S, Tarnow L, Rossing P, Hansen B, Parving H-H: Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000; 57: 601-606.